Leadership
Board of Directors
Advisors

About Us

Arcturus Therapeutics a global late-stage messenger RNA medicines and vaccines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

http://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Large.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Small.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_large.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_thumb.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF-scaled.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF_230.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/ArcBuilding_Final.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/building_external_thumbnail.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF-scaled.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF_230.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-exterior.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/main_office_exterior_thumbnail.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-interior-tag-line.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/building_tagline_thumbnail.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo-scaled-1.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo_thumbnail.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo-scaled-1.jpg
http://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo_thumbnail.jpg
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
June 4, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina
READ MORE
August 15, 2013
San Diego upstart acquires RNA tech from cash-strapped Marina Biotech
READ MORE
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
READ MORE
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
READ MORE
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
READ MORE
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
READ MORE
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
READ MORE
August 9, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
READ MORE
August 18, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
READ MORE
August 31, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
READ MORE
September 1, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
READ MORE
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
READ MORE
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
READ MORE
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
READ MORE
December 12, 2022
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
READ MORE
December 13, 2022
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
READ MORE
December 19, 2022
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
READ MORE
January 31, 2023
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
READ MORE
March 28, 2023
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
READ MORE